Ethel Weld, MD

CRS:

JHU

Role:

Email:

eweld@jhmi.edu
  • Protocol chair, IMPAACT 2005
  • Protocol vice-chair, IMPAACT 2022
  • Member, Clinical Pharmacology Advisory Group of the ACTG Laboratory Steering Committee (2018-Present)
  • Member, ACTG Antiretroviral Therapy Strategies Transformative Science Group Less Frequent Dosing ART Working Group
  • Member, Pharmacology Core, HPTN Laboratory Core
  • Member, TB in Pregnancy Working Group
  • Protocol pharmacologist for HPTN 086, IMPAACT CAP 544, IMPAACT CAP 543

Categories

Leadership Committees
CRS
Roles

Clinical Trials

Identification of Biomarkers That Can Predict Progression...

Purpose: The C-TRIUMPH study has identified 20 household contacts (HHC), who have progressed to active TB from its HHCs cohort...

Read More

A5329: Interferon –Free Therapy for Chronic Hepatitis C...

A5329 is a study for people who are infected with both HIV and the Hepatitis C virus (HCV) and have never taken Hepatitis C...

Read More

A5225: Phase I/II Dose-Finding Study of High-Dose...

A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...

Read More

A5332: Randomized Trial to Prevent Vascular Events in HIV...

REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....

Read More

The Pharmacokinetics, Safety and Acceptability of New...

PK, safety and acceptability data and practical guidance on the optimal dosing of new more child-friendly formulations of...

Read More